Introduction {#s1}
============

Usher syndrome is a genetically heterogeneous autosomal recessive disorder characterized by early onset sensorineural hearing loss and later onset retinitis pigmentosa (RP). Mutations in the *USH2A* gene are the most common cause of Usher syndrome type I ([@bib2]; [@bib6]; [@bib9]) and are also a common cause of non-syndromic RP ([@bib36]; [@bib62]). The combination of hearing loss and retinitis pigmentosa in Usher syndrome creates an unusual opportunity for the development of effective gene replacement therapy. Unlike many other forms of retinitis pigmentosa in which a large fraction of the photoreceptors have already been lost by the time a diagnosis is made, newborn hearing tests coupled with increasingly sensitive molecular testing have the potential to identify patients affected with Usher syndrome early enough that the majority of their photoreceptors are still amenable to gene replacement therapy.

The obstacles to such treatment include the large size of the *USH2A* gene, which precludes the use of the types of viral vectors currently employed for retinal gene therapy. Large genes also frequently harbor a number of rare variants of uncertain pathogenicity in the population, and these can make it difficult to establish a molecular diagnosis with sufficient certainty to undertake a therapy as invasive as subretinal injection of therapeutic viruses. Another obstacle to treatment is the relative paucity of information about the normal function of the protein encoded by *USH2A* (usherin) and the degree to which it can be overexpressed in human cells without causing harm.

The advent of induced pluripotent stem cells (iPSCs) ([@bib56]) and the ability to make tissue-specific progenitors from these cells have created a path for overcoming many of these obstacles. It is now possible to investigate the function and dysfunction of a disease-associated gene in tissues such as retina that are inaccessible to molecular analysis in living patients ([@bib61]; [@bib19]; [@bib53]). For instance, in a recent study, we sequenced the exome of an individual with RP who had no family history of eye disease and only one living sibling and identified a likely disease-causing homozygous mutation in a gene (MAK) that had not been previously reported to be associated with disease ([@bib61]). We validated this finding in a large cohort of RP patients and then used fibroblast-derived iPSCs from the proband to investigate the mechanism through which the mutation causes disease ([@bib61]).

The generation of iPSCs from older individuals is more difficult and less efficient than the generation of iPSCs from young individuals ([@bib33]). To help overcome this limitation, a variety of different reprogramming factors, reprogramming enhancers, and cell types have been evaluated ([@bib28]; [@bib20]; [@bib34]; [@bib8]; [@bib42]; [@bib55]; [@bib64]; [@bib27]; [@bib29]; [@bib31]; [@bib33]; [@bib44]; [@bib65]). Of the accessible cell types used for iPSC generation, the reprogramming of keratinocytes has been shown to be as much as 100-fold more efficient and at least twofold faster than the reprogramming of dermal fibroblasts ([@bib1]). In addition, it has recently been shown that keratinocyte-derived iPSCs are more similar to embryonic stem cells than those generated from fibroblasts ([@bib5]).

The ability to create otherwise inaccessible tissues like retina from patient-derived iPSCs provides a valuable tool for the study of disease pathophysiology and the development of treatment. However, the utility of this approach is limited by one's ability to generate relatively pure cultures of the cell type of interest. As clearly demonstrated in a variety of recent publications, early passage iPSCs tend to retain an epigenetic profile that is characteristic of their somatic tissue of origin ([@bib35]; [@bib21]). An excellent example of how epigenetic memory can influence retinal differentiation is the recent study by Clegg et al. ([@bib17]), who showed that iPSCs generated from retinal pigmented epithelium (RPE) would preferentially re-differentiate into mature RPE. Although viable retinal tissue suitable for iPSC generation would be difficult to obtain for the purpose of patient-specific disease modeling and therapy, accessible somatic cells from the same germ lineage as the neural retina are readily available in the form of keratinocytes.

In addition to being a useful tool for investigation of disease pathophysiology, iPSC technology provides a means for future autologous photoreceptor transplantation for the treatment of retinal degeneration. Work from Ali et al. clearly demonstrates that the post-mitotic photoreceptor precursor cell is the optimal cell type for efficient rod photoreceptor cell replacement ([@bib22]; [@bib48]). A variety of different protocols, utilizing both two- and three-dimensional culture systems, have succeeded in deriving photoreceptor precursor cells from less differentiated precursors ([@bib45]; [@bib13]; [@bib39]; [@bib46]; [@bib24]; [@bib38]; [@bib59]; [@bib41]; [@bib50]; [@bib51]; [@bib16]; [@bib37]; [@bib58]). Although cultured three-dimensional eyecups will undoubtedly have many applications in developmental biology ([@bib41]; [@bib51]), two-dimensional systems have the advantage of easier identification and isolation of specific cell types for post-differentiation subculture. We and others have shown that following transplantation, iPSC-derived photoreceptor precursor cells give rise to rod and cone photoreceptor precursors, which integrate within the dystrophic retina, form synapses with host bipolar cells, and induce a partial restoration of electrophysiological and anatomical correlates of retinal function ([@bib24]; [@bib59]; [@bib16]). Isolation of specific cell types from two-dimensional iPSC-derived eyecups followed by transplantation into animal eyes provides a means for exploring human retinal pathophysiology in unprecedented detail, as well as a means for efficiently evaluating gene-based and cell-based therapies.

In this study, we combined Sanger sequencing, next-generation sequencing, and iPSC technologies to identify the disease-causing *USH2A* mutations in a 62-year-old patient with retinitis pigmentosa and to demonstrate that the mutations we identified are present in the patient's retinal transcripts. In addition, we were able to show that the patient's iPSC-derived rod photoreceptor precursor cells could integrate within the immune suppressed developing mouse retina and give rise to morphologically and immunohistochemically recognizable photoreceptor cells. These findings suggest that the *USH2A* mutations in this patient act via post-developmental photoreceptor degeneration rather than an early developmental abnormality.

Results {#s2}
=======

Genomic DNA from a patient affected with autosomal recessive retinitis pigmentosa (RP) was fragmented and hybridized to an Agilent exome capture reagent (v2), and the eluted fragments were sequenced on an Illumina sequencing instrument. This experiment yielded 71 million uniquely mapped paired-end sequences, each end 50 bp in length. These sequences were aligned to the reference human genomic sequence (hg19) using BWA ([@bib26]) and BFAST ([@bib15]). Departures from the reference were identified with GATK ([@bib9]). More than 20,000 sequence variations were detected ([Supplementary file 1B](#SD1-data){ref-type="supplementary-material"}). These variants were prioritized using the following criteria: GATK variation quality score greater than 50, presence in coding sequence or within 5 bp of a splice junction, annotated frequency of less than 2% in all available population databases, presence in two or fewer exome sequences from other individuals analyzed by our laboratory, predicted to alter protein structure, and lack of complete genotype sharing with the proband's unaffected sibling (as determined by genomewide SNP genotyping) ([Supplementary file 1B](#SD1-data){ref-type="supplementary-material"}). After applying these filters to the data, more than 400 plausible disease-causing sequence variations, in more than 300 genes, remained for further consideration. There were no instances of two plausible disease-causing variants in a gene previously associated with RP, but two human retinal degeneration genes (*ABCA4* and *USH2A*) each harbored a single plausible disease-causing variant (Thr1428Met ACG\>ATG and Arg4192His CGC\>CAC, respectively). Sanger sequencing of the entire coding sequence of both of these genes confirmed the presence of the heterozygous variants identified by exome sequencing but failed to detect a second disease-causing variation in either gene. We then began evaluating genes that had not been previously associated with human retinal disease that contained two protein-altering variants in the proband. As we were screening additional RP patients and controls for these variants, two things occurred that re-directed our attention to *USH2A*. First, we discovered a second RP patient with the Arg4192His variant in *USH2A*, and this individual had a second well-established disease-causing mutation on the opposite *USH2A* allele. More importantly, [@bib62] published their discovery of a disease-causing variant in intron 40 of *USH2A*. Sanger sequencing of intron 40 in our patient revealed this intronic variant to be present in *trans* to his Arg4192His mutation.

To validate the pathogenicity of these mutations in retinal tissue, and to begin developing a cell replacement therapy, we developed an iPSC line from our patient using a primary culture of keratinocytes as the starting material. Like retina, keratinocytes are of ectodermal origin and are significantly easier to reprogram than fibroblasts ([@bib1]). This is especially important when trying to generate iPSCs from older individuals.

The proband's keratinocytes ([Figure 1A](#fig1){ref-type="fig"}) were expanded for three passages prior to being reprogrammed into iPSCs ([@bib58]). For iPSC generation, passage-4 cells were plated at a density of 30,000 cells/cm^2^ and transduced with the transcription factors OCT4, SOX2, KLF4, and C-MYC. Approximately, 7 days post-transduction, cells were passaged at a density of 10,000 cells/cm^2^ onto fresh Synthemax cell culture plates and fed every other day with fresh iPSC induction media. 2--3 weeks following the initial passage, small, morphologically distinct cell clusters were present ([Figure 1B](#fig1){ref-type="fig"}). 2--3 weeks later, cell colonies large enough for mechanical isolation were dissected from the surrounding differentiated keratinocyte layer. Each isolated colony was dissociated into 150--200 μm square cell clusters and cultured in individual wells of a 24-well Synthemax cell culture plate. Each well was maintained as a separate clonally expanded line for four passages prior to analysis. At passage 4, cultures contained well-defined densely packed colonies consisting of cells with a high nucleus to cytoplasm ratio ([Figure 1C](#fig1){ref-type="fig"}, RP-iPSC). To test pluripotency, rt-PCR and teratoma assays were performed. rt-PCR analysis confirmed expression of the pluripotency markers DNMT, LIN28, OCT4, KLF4, SOX2, Nanog, and C-MYC ([Figure 1D](#fig1){ref-type="fig"}).10.7554/eLife.00824.003Figure 1.Derivation of iPSCs from keratinocytes of a patient affected with *USH2A*-associated RP.(**A**--**H**) Microscopic analysis of human keratinocytes (**A**), early keratinocyte-derived iPSC colonies (**B**, arrows), and purified keratinocyte-derived iPSC cultures (**C**). At 2--3 weeks post-viral transduction, ES-cell-like iPSC colonies begin to emerge (**B**, arrows). iPSC colonies isolated, subcultured, and expanded on Synthemax cell culture surfaces maintain a pluripotent morphology (**C**) express the pluripotency markers DNMT, LIN28, OCT4, KLF4, SOX2, NANOG, and C-MYC (**D**), and form teratomas consisting of tissues of ectoderm (**E**, arrow and **G**, GFAP in green), mesoderm (**F**, asterisk and **H**, SMA in red), and endoderm (**F**, arrows) each of the three embryonic germ layers (**E**--**H**). Scale bar = 400 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.00824.003](10.7554/eLife.00824.003)

Histologic analysis of teratomas revealed tissues specific to each of the three embryonic germ layers ([Figure 1E,F](#fig1){ref-type="fig"}). Similarly, immunohistochemical staining revealed GFAP positive neural tissue ([Figure 1G](#fig1){ref-type="fig"}) and αSMA positive vascular structures ([Figure 1H](#fig1){ref-type="fig"}).

To derive retinal neurons from these iPSCs for pathophysiologic studies and the development of patient-specific therapy, a slightly modified version of our previously published stepwise differentiation protocol was used ([Figure 2A](#fig2){ref-type="fig"}) ([@bib59], [@bib61], [@bib58]). This protocol is designed to maximize the percentage of retinal cells produced by taking into account: (1) the role of bone morphogenic protein (BMP) and Wnt signaling pathway inhibition in neuroectodermal development (noggin and DKK1, respectively) ([@bib23]; [@bib40]; [@bib3]); (2) the role of IGF-1 in anterior neural/eye field development ([@bib49]); and (3) Notch pathway inhibition (DAPT---gamma secretase inhibitor) in photoreceptor cell development ([@bib18]). Although retinal differentiation in mouse can be accomplished in 30 days ([@bib59], [@bib58]), retinal differentiation of human cells takes significantly longer. During differentiation, these keratinocyte-derived iPSCs formed eyecup-like structures with clearly defined layers of pigmented RPE and non-pigmented neural retina ([Figure 2B--E](#fig2){ref-type="fig"}). This was a clear departure from our previous experience with fibroblast-derived iPSCs, which never develop eyecup-like structures under very similar culture conditions. The eyecups began as small pigmented foci that could be detected as early as 45 days post-differentiation ([Figure 2B](#fig2){ref-type="fig"}). Following passage and continued differentiation, these pigmented clumps expanded and elongated over 150 days ([Figure 2C](#fig2){ref-type="fig"}) and were eventually joined by a clump of neural rosettes ([Figure 2C](#fig2){ref-type="fig"}, arrow) on one side of the pigmented structure. In some cases, these RPE/neural units extended into C-shaped eyecup-like structures ([Figure 2D,E](#fig2){ref-type="fig"}) while in others, the central cavity did not form and the structure consisted of a circular sheet of neural cells surrounded by a pigmented epithelium ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). In many cases, multiple eyecups at different developmental stages were present within the same well of a differentiating six-well plate ([Figure 2D](#fig2){ref-type="fig"}, arrows). The reason that these eyecup-like structures develop in a planar fashion instead of the spheres reported by both Meyer et al. and Eiraku et al. is that we grow these cells under adherent conditions in tissue culture dishes coated with collagen, laminin, and fibronectin, while spheres are grown in suspension ([@bib38]; [@bib11]). Although there will undoubtedly be advantages of both approaches in different situations, two advantages of this planar system is that the neural cells in the center of the eyecup do not necrose for lack of oxygen, and the firm attachment to the underlying substrate allows homogeneous biopsies to be taken from the eyecups for subculture and analysis.10.7554/eLife.00824.004Figure 2.Differentiation of human *USH2A*-associated iPSCs into eyecup-like structures.(**A**) Schematic diagram illustrating the differentiation paradigm utilized to generate human eyecup-like structures. (**B**--**E**) Morphological analysis of *USH2A*-associated iPSC-derived eyecups. iPSC-derived eyecups form pigmented cell clumps (**B**) that extend and wrap in a C shape around newly formed neural rossettes (**C**). Following this protocol, a typical six-well cell culture dish will have two to four eyecups/well, each at slightly different stages of development (**D**, arrows, a low magnification image of a typical well of a six-well plate with developing eyecups). At 150 days post-differentiation, complete eyecups with clearly defined neural retina and RPE layers can be identified (**D**, top right arrow, and **E**). Scale bar, **B** and **C** = 200 μm, **D** = 400 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.00824.004](10.7554/eLife.00824.004)10.7554/eLife.00824.005Figure 2---figure supplement 1.Additional examples of human *USH2A*-associated iPSC-derived eyecup-like structures.(**A**--**C**) At 150 days post-differentiation, extensive neural rosette formation was present. (**D**--**F**) Immunocytochemical analysis targeted against recoverin and rhodopsin confirms that neural rosettes consisted predominantly of rod photoreceptor precursor cells.**DOI:** [http://dx.doi.org/10.7554/eLife.00824.005](10.7554/eLife.00824.005)

For example, to explore the cellular makeup of the pigmented layer of the eyecups ([Figure 3A](#fig3){ref-type="fig"}), biopsies were taken, gently dissociated, and subcultured for subsequent expansion and microscopic analysis. 24 hr after plating, pigment-containing cell clusters adhered to the culture surface and began to give rise to non-pigmented cells with a fibroblastic morphology ([Figure 3B](#fig3){ref-type="fig"}). By 72--96 hr post-plating, extensive cell spreading and a complete loss of pigmentation was noted ([Figure 3C](#fig3){ref-type="fig"}). By 2 weeks post-plating, confluent cultures of densely pigmented hexagonal epithelial cells were present ([Figure 3D](#fig3){ref-type="fig"}). Immunocytochemical analysis of these cultures revealed cells expressing the tight junction marker ZO1 ([Figure 3E](#fig3){ref-type="fig"}), the transcription factor PAX6 ([Figure 3F](#fig3){ref-type="fig"}), the RPE-specific channel bestrophin ([Figure 3---figure supplement 1A](#fig3s2){ref-type="fig"}) and the RPE visual cycle protein RPE65 ([Figure 3---figure supplement 1B](#fig3s2){ref-type="fig"}). To further investigate the identity of cells within the pigmented layer of patient-specific eyecups, TEM analysis was performed. As shown in [Figure 3](#fig3){ref-type="fig"}, cells within the pigmented layer contained pigment granules (**G**, asterisks), tight junctions with neighboring cells (**G** and **H**, arrows), and apical microvilli (**G** and **H**, arrowheads), all of which are characteristic of native RPE. Collectively, these results indicate that the pigmented layer of cells located at the perimeter of patient-specific eyecups is patient-specific RPE.10.7554/eLife.00824.006Figure 3.Cells contained within the pigmented layer of *USH2A*-associated eyecups are of RPE origin.(**A**) A high magnification phase image of the RPE layer of an *USH2A* eyecup prior to biopsy and subculture. (**B**--**D**) Area of the RPE presented in panel **A** was picked and subcultured in fresh RPE culture media on collagen, laminin, and fibronectin coated six-well culture dishes. 24 hr after plating, RPE cells spread and take on a fibroblastic morphology (**B**). By 72 hr post-plating, RPE cells lose their pigmentation and begin to form cell--cell contacts (**C**). 2 weeks post-plating, a confluent monolayer of RPE cells are present that have taken on the typical cuboidal RPE morphology and regained pigmentation (**D**). (**E--F**) Immunocytochemical analysis of *USH2A*-associated RPE cells with antibodies targeted against the tight junction marker ZO1 (**E**) and the transcription factor PAX6 (**F**). (**G**--**H**) TEM analysis of RPE cells within the intact RPE layer of *USH2A* eyecups (**H** is a high magnification view of the upper right corner of panel **G**). RPE cells are polarized, have apical microvilli, make tight junctions with neighboring RPE cells (**G** and **H**, arrows) and contain pigment granules within their cytoplasm (**G**, asterisk). Scale bar, **B**--**D** = 200 μm, **G** = 0.5 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.00824.006](10.7554/eLife.00824.006)10.7554/eLife.00824.007Figure 3---figure supplement 1.Pigmented cells isolated from *USH2A*-associated eyecups express bestrophin 1 and RPE65.(**A** and **B**) Immunocytochemical analysis of subcultured *USH2A*-associated RPE cells with antibodies targeted against bestrophin 1 (**A**) and RPE65 (**B**).**DOI:** [http://dx.doi.org/10.7554/eLife.00824.007](10.7554/eLife.00824.007)

To determine whether cells contained within non-pigmented neural rosettes ([Figure 4A](#fig4){ref-type="fig"}) had adopted a photoreceptor cell fate, patient-specific eyecups were fixed and analyzed with both TEM ([Figure 4B](#fig4){ref-type="fig"}) and confocal microscopy using antibodies to the rod photoreceptor markers recoverin and rhodopsin ([Figure 4C--E](#fig4){ref-type="fig"}, and [Figure 2---figure supplement 1D--F](#fig2s1){ref-type="fig"}), and recoverin the connecting cilium marker acetylated tubulin ([Figure 4F--H](#fig4){ref-type="fig"}). Densely packed neural rosettes contained polarized recoverin positive cells ([Figure 4C,E,F, and H](#fig4){ref-type="fig"}, and [Figure 2---figure supplement 1D--F](#fig2s1){ref-type="fig"}, green) with acetylated tubulin ([Figure 4D,E](#fig4){ref-type="fig"}, red) and rhodopsin ([Figure 4G,H](#fig4){ref-type="fig"}, and [Figure 2---figure supplement 1D--F](#fig2s1){ref-type="fig"}, red) positive structures concentrated at the luminal surface of the rosettes. TEM analysis further confirmed the existence of cilia with clearly identifiable basal bodies ([Figure 4B](#fig4){ref-type="fig"}, arrowhead).10.7554/eLife.00824.008Figure 4.iPSC-derived USH2A-associated neural retinal rosettes consist predominantly of rod photoreceptor cells.(**A**) Morphological depiction of the neural retina at 120 days post-differentiation. (**B**) TEM analysis of neural rosettes demonstrates the existence of cilia with clearly identifiable basal bodies. (**C**--**H**) Immunocytochemical analysis targeted against the rod photoreceptor markers recoverin and rhodopsin (**C**--**E** and **Ei**-high magnification inlay), and the rod photoreceptor marker recoverin and the connecting cilia marker acetylated tubulin (**F**--**H** and **Hi**-high magnification inlay).**DOI:** [http://dx.doi.org/10.7554/eLife.00824.008](10.7554/eLife.00824.008)

In an attempt to determine the developmental timeline of retinal gene expression, a series of rt-PCR and western blot analyses were performed on retinal progenitor cultures isolated at 60, 90, and 120 days post-differentiation. The retinal transcripts *PAX6*, *OTX2*, *CRX*, *NRL*, recoverin, and rhodopsin were detected in differentiating patient-specific iPSCs as early as 60 days post-differentiation ([Figure 5A](#fig5){ref-type="fig"}). However, the mature rod photoreceptor protein recoverin and the rod photopigment rhodopsin were not detected until 90 and 120 days post-differentiation, respectively ([Figure 5B](#fig5){ref-type="fig"}). Similarly, the cone photopigments blue opsin and red/green opsin were first detected at 90 and 120 days post-differentiation, respectively ([Figure 5B](#fig5){ref-type="fig"}).10.7554/eLife.00824.009Figure 5.Developmental timeline of neural retina marker expression.(**A**) RT-PCR analysis of *USH2A* and human control neural retina for expression of the retinal transcription factors/photoreceptor markers PAX6, OTX2, CRX, NRL, recoverin, and rhodopsin at 60 days post-differentiation. (**B**) Western blot analysis of *USH2A* neural retina for expression of the retinal photoreceptor markers recoverin, rhodopsin, blue cone opsin and red/green cone opsin at 60, 90, and 120 days post-differentiation. Although retinal transcripts can be detected as early as 60 days post-differentiation, mature photoreceptor proteins such as recoverin, rhodopsin, and the cone opsins could not be detected until 90 to 120 days post-differentiation.**DOI:** [http://dx.doi.org/10.7554/eLife.00824.009](10.7554/eLife.00824.009)

To determine whether *USH2A* was expressed in iPSC-derived neural retina and whether the mutations we identified in the genomic DNA affected the *USH2A* gene product, rt-PCR analysis of RNA isolated from human control retina, control iPSC-derived photoreceptor precursor cells, and patient-specific iPSC-derived photoreceptor precursor cells were performed. As shown in [Figure 6](#fig6){ref-type="fig"}, RNA isolated from patient-specific iPSC-derived photoreceptor precursor cells revealed that the suspected splice site mutation identified in intron 40 of the proband caused exonification of the intron ([Figure 6A](#fig6){ref-type="fig"}). Introduction of intronic sequence between exons 40 and 41 results in a frame shift and introduction of a premature stop codon. Similarly, Sanger sequencing of rt-PCR products generated from the iPSC-derived photoreceptor precursor cells allowed us to confirm the single point mutation identified within exon 63 of the patients' DNA ([Figure 6B](#fig6){ref-type="fig"}). In an attempt to determine the pathophysiological mechanism of these mutations, a series of western blot experiments were performed to look for evidence of mutation-induced apoptosis, ubiquitination, and ER stress. As shown in [Figure 6C](#fig6){ref-type="fig"}, when compared to normal human retina, iPSC-derived photoreceptor precursor cells from a normal control and a separate RP patient with known disease-causing mutations and pathophysiology (MAK associated RP caused by nonsense mediated decay of the transcript), the proband was found to have increased expression of the markers GRP78 and GRP94 indicative of protein misfolding and subsequent ER stress ([@bib43]; [@bib30]).10.7554/eLife.00824.010Figure 6.Confirmation of genomic *USH2A* variants in iPSC-derived neural retina.(**A**) RT-PCR analysis of USH2A exons 39 to 41 in human control retina ([@bib9]), human control iPSC-derived neural retina ([@bib6]), and human RP iPSC-derived neural retina. An intronic splice site mutation in intervening sequence 40 of the USH2A gene results in the introduction of a pseudoexon (IVS40 Red) causing a translation frameshift and a premature stop codon. (**B**) RT-PCR analysis of *USH2A* exon 62 to 63 in human control human retina ([@bib9]), human control iPSC-derived neural retina ([@bib6]), and human RP iPSC-derived neural retina. A single heterozygous point mutation identified by whole exome sequencing (Arg4192His) was confirmed in the proband's retinal transcript. (**C**) Western blot analysis of protein isolated from human control retina and iPSC-derived photoreceptor precursor cells obtained from the proband, an unaffected control, and a separate RP patient with known disease pathophysiology for expression of the ER-stress markers GRP78 and GRP94. Elevated expression of both GRP78 and GRP94 suggests that the mutations identified within the proband result in protein misfolding and ER-stress. \*\*p\<0.001**DOI:** [http://dx.doi.org/10.7554/eLife.00824.010](10.7554/eLife.00824.010)

For patients who have lost the majority of their retinal photoreceptor cells and in turn the majority of their vision, our ultimate goal is to develop a patient-specific autologous cell replacement strategy that can repopulate the outer retina with functional photoreceptors. The ability to transplant such cells into animals with retinal degeneration will also be valuable as part of the vision scientist's armamentarium for exploring the pathophysiologic mechanism of specific mutations that are identified in patients. To test whether patient-specific photoreceptor precursor cells isolated from the neural retina layer of human iPSC-derived eyecups could give rise to new photoreceptor cells in animals for the latter purpose, a series of transplantation experiments were performed. It has been previously shown that the optimal cell type for retinal transplantation is the post-mitotic photoreceptor precursor cell ([@bib32]; [@bib48]). Prior to transplantation, 150-day neural rosettes were dissected free from their surrounding tissues and plated onto fresh tissue culture plates to determine whether these cells would maintain a photoreceptor cell identity following dissociation. To test this, cell cultures were infected 3 days after plating with a lentiviral vector driving expression of GFP under control of the rhodopsin kinase promoter. 2 weeks after plating, post-mitotic rhodopsin kinase positive photoreceptor precursor cells were abundant ([Figure 7A,B](#fig7){ref-type="fig"}). In many instances, clusters of the rhodopsin kinase positive cells realigned in a polarized photoreceptor cell fashion and extended axon-like projections ([Figure 7B](#fig7){ref-type="fig"}, arrowhead) and outer-segment-like processes ([Figure 7B](#fig7){ref-type="fig"}, arrow). Following the confirmation of a stable photoreceptor cell fate, newly generated 150-day photoreceptor precursor cells were transplanted into the subretinal space of P4 immunodeficient *Rag1*^*−/−*^ x *Crb1*^*−/−*^ mice. *Crb1*^*−/−*^ mice were chosen as recipient animals because they exhibit a relatively slow retinal degeneration and also because they are known to be more conducive to cellular integration with proper rod photoreceptor morphology following transplantation than other retinal degenerative strains ([@bib4]).10.7554/eLife.00824.011Figure 7.*USH2A*-associated photoreceptor precursor cells integrate into the dystrophic mouse retina and develop into mature photoreceptor cells.(**A** and **B**) Microscopic analysis of rhodopsin kinase GFP expression in 150-day photoreceptor precursor cells at 14 days post-plating. (**C**--**E**) Immunocytochemical analysis performed on the retinas of *Rag*^*−/−*^ x *Crb1*^*−/−*^ degenerative eyes 14 days after receiving subretinal injections of patient-specific photoreceptor precursor cells targeted against expression of the human cell antigen Tra-1-85 (**C**--**F**) and the photoreceptor marker recoverin (**D** and **E**). Scale bar = 50 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.00824.011](10.7554/eLife.00824.011)10.7554/eLife.00824.012Figure 7---figure supplement 1.*USH2A*-associated photoreceptor precursor cells integrate into the dystrophic mouse retina.Immunocytochemical analysis performed on the *Rag*^*−/−*^ x *Crb1*^*−/−*^ degenerative eyes 14 days after receiving subretinal sham injections targeted against expression of the human cell antigen Tra-1-85. ONL, outer nuclear layer; OPL, outer plexiform layer; and INL, inner nuclear layer.**DOI:** [http://dx.doi.org/10.7554/eLife.00824.012](10.7554/eLife.00824.012)

2 weeks after transplantation, extensive cellular integration was detected using the human Tra-1-85 blood antigen as a marker of human cells ([Figure 7C--F](#fig7){ref-type="fig"}, [Figure 7---figure supplement 1](#fig7s3){ref-type="fig"}, Sham injection control, red). The integrated cells expressed the mature photoreceptor marker recoverin, extended axonal projections toward the inner plexiform layer ([Figure 7D--F](#fig7){ref-type="fig"} arrowheads), and developed inner- and outer-segment-like projections that extended toward the underlying RPE layer ([Figure 7D--F](#fig7){ref-type="fig"} arrows).

Discussion {#s3}
==========

Patient-specific iPSC-derived retinal cells are a valuable new tool for investigators seeking to understand and treat degenerative retinal diseases. These cells will allow scientists to explore the pathophysiology of human diseases in ways that were previously possible only in animal models. They will also be useful for evaluating potential therapies ranging from high-throughput screens of small molecule drugs to the comparison of gene replacement constructs containing different promoters or packaged in different vectors. For rare autosomal recessive disorders such as *USH2A*-associated RP, there is often little statistical evidence for the pathogenicity of one or both of a patient's putative disease-causing mutations. In such cases, iPSC-derived retinal cells may be useful for confirming the pathogenicity of an unusual genotype before embarking upon an invasive therapy like subretinal administration of viral-mediated gene therapy.

In this study, we combined sequencing and iPSC technologies to identify and confirm the pathogenicity of disease-causing mutations in an isolated patient with autosomal recessive RP. Exome sequencing of this individual revealed more than 400 plausible disease-causing sequence variations in more than 300 genes. Two of these were present in genes known to cause autosomal recessive RP (an Arg4192His variant in *USH2A* and a Thr1428Met in *ABCA4*), but a second disease-causing allele could not be found in either of these genes despite Sanger sequencing of the entire coding sequence. We were fortunate that Vaché et al. identified and reported the *USH2A* variant in IVS 40 that proved to be our patient's second disease-causing allele. Non-exomic mutations are not an uncommon cause of recessive diseases. In some instances (e.g., *CEP290*-associated LCA) they account for the largest proportion of disease-causing alleles ([@bib54]). As the iPSC technology becomes more routine, the evaluation of RNA from iPSC-derived retina may become a common step in the analysis of exome sequencing data when two clearly disease-causing alleles cannot be identified in known disease genes. To confirm the pathogenicity of the *USH2A* variants we observed in our patient, *USH2A* transcripts were analyzed using RNA isolated from iPSC-derived photoreceptor precursor cells obtained from the proband, an unaffected control and human donor retina. The suspected splice site mutation within IVS40 was shown to cause exonification of the intron, a translation frameshift and a premature stop codon. The transcription of the patient's *USH2A* missense mutation was confirmed in a similar fashion. In combination, these mutations resulted in an upregulation of the markers GRP78 and GRP94 indicative of protein misfolding and subsequent ER stress.

Following transplantation into neonatal retinal degenerative *Crb1* mutant mice, our patient's photoreceptor precursor cells integrated into the outer nuclear layer and differentiated into morphologically and immunohistochemically recognizable photoreceptors. This finding is compatible with our patient's history of normal vision until the third decade of life; that is, his *USH2A* mutations do not appear to cause a gross developmental abnormality of photoreceptor cells. It is also noteworthy that transplantable photoreceptor precursor cells could be generated from the skin of a patient in the seventh decade of life. The transplantation of photoreceptor precursor cells derived from early postnatal retina or embryonic stem cells has been accomplished before by other groups ([@bib32]; [@bib25]; [@bib48]), but to our knowledge, this is the first time that photoreceptor precursor cells have been derived from an adult human RP patient and successfully transplanted into mice. However, much work remains to be done before such transplants could be considered evidence for the feasibility of sight-restoring iPSC-derived treatments in humans. For example, synaptic connectivity will need to be demonstrated ultrastructurally and electrophysiologically, and useful vision in treated animals will need to be demonstrated with an array of psychophysical approaches. Longevity of the transplanted cells will be important to demonstrate as will the cells' lack of tumorigenicity. For such transplants to have practical clinical utility it will also be important to show that the transplanted cells can integrate and function in the retinas of animals with advanced stages of many different molecular types of retinal degeneration.

Unlike many of the genes targeted in current clinical trials, *USH2A* is very large and will be impossible to package into the viral vectors in current clinical use. The coding sequence of *USH2A* is \>18 kb, and the packaging limits of AAV and EIAV vectors are about 3 kb and 10 kb, respectively. For genes such as *USH2A*, vectors with large carrying capacities such as HSV1, which can accommodate inserts of up to 40 kb in size ([@bib57]), may be useful. In addition to the vector limitations, the proper stoichiometry of the delivered message will also be critical for some genes. It is possible that patients like the one reported here, with a truncated protein encoded by one allele and a misfolded protein encoded by the other, may require a different promoter and multiplicity of infection than a different patient who harbors two stop mutations in *USH2A*. Patient-specific iPSC-derived retinal cells may be useful in choosing the optimal gene therapy strategy for each individual.

For late-stage *USH2A*-associated RP where significant photoreceptor cell loss has occurred, cell replacement strategies will be required to restore vision. In some cases, correcting the genetic defect responsible for the photoreceptor degeneration will be necessary before transplanting photoreceptor cells into the patient. The development of site specific TALEN- or CRISPR-based genome editing approaches, which allow for the targeted correction of patient-specific cells in vitro, is proving to have great utility for endogenous gene correction ([@bib14]; [@bib10]; [@bib63]). For instance, Hockemeyer et al. recently demonstrated that for the five genomic sites targeted, pluripotent iPSC clones carrying transgenes solely at TALEN-specified loci could be obtained ([@bib14]). Similarly using the CRISPR/CAS-9 system, Wang et al. recently demonstrated the ability to simultaneously manipulate five separate genetic loci in mouse ES cells ([@bib63]). A major advantage of these approaches is that unlike exogenous gene addition in which promoter strength and multiplicity of infection may require patient-specific adjustment, TALEN- and CRISPR-mediated correction have the advantage that the gene remains under the control of the endogenous promoter. For recessive diseases such as *USH2A*-associated RP, correction of a single disease-causing allele should be sufficient for a therapeutic effect. One could test this directly by transplanting corrected cells into retinal degenerative mice and determining whether cells with both alleles corrected behave differently than those with one or neither allele corrected.

It is possible that for some individuals with late-onset disease, such as the patient described in this report, genetic correction prior to transplantation may not be required. That is, if the patient's native photoreceptor cells develop and function normally until the third decade of life, as suggested by our current data and the patient's clinical history, it is possible that replacement of lost photoreceptors with iPSCs that have not been genetically modified could be a reasonably durable treatment.

An alternative approach to patient-specific autologous cell replacement that would also not require genetic manipulation of the donor cell population prior to delivery would be the use of either genetically unmatched ES or tissue-specific precursor cells. This approach is currently in clinical trial for the treatment of Stargardt macular dystrophy and age-related macular degeneration (AMD) ([@bib52]). In these studies, ES cell-derived retinal-pigmented epithelial cells are delivered to immune suppressed patients as subretinal bolus cell injections ([@bib52]). However, there are considerable disadvantages to using allogeneic cells. Retinas injured by inherited disease often have a loss of integrity of the blood retinal barrier, which would allow the patient's peripheral immune system access to the transplanted cells. This type of transplant approach would likely require life-long immunomodulation, ([@bib12]) putting patients at further risk.

In summary, by combining next-generation and Sanger sequencing with iPSC technologies we were able to demonstrate the pathogenicity of two disease-causing mutations in a patient with non-syndromic *USH2A*-associated RP. We also demonstrated that keratinocytes cultured from a patient in the seventh decade of life can be reprogrammed into iPSCs and differentiated into a multi-layered eyecup-like structure with immunohistochemical and ultrastructural features of human retinal precursor cells. Finally, we showed that these patient-derived retinal precursor cells have the ability to integrate into the developing mouse retina and to form morphologically and immunohistochemically recognizable photoreceptor cells. These findings will enable patient-specific studies of disease mechanism, gene correction, and photoreceptor cell transplantation for many different types of human retinal degeneration.

Materials and methods {#s4}
=====================

Ethics statement {#s4-1}
----------------

All experiments were conducted with the approval of the University of Iowa Animal Care and Use Committee (Animal welfare assurance \#1009184) and the University of Iowa Internal Review Board (IRB \# 200202022). All experiments were consistent with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and the Treaty of Helsinki.

Patient-derived cells {#s4-2}
---------------------

After informed consent, skin biopsies were collected from a 62-year-old patient with an unknown cause of RP, three patients with known causes of retinal disease and three individuals without eye disease, and these were used for fibroblast and keratinocyte isolation (as described previously \[[@bib7]; [@bib58]\]). Cells were expanded and targeted for iPSC generation.

iPSC generation {#s4-3}
---------------

iPSCs were generated from human patient-specific keratinocytes via infection with four separate non-integrating Sendai viruses, each of which were designed to drive expression of one of four transcription factors: OCT4, SOX2, KLF4, and c-MYC (A1378001, Invitrogen, Grand Island, NY). Keratinocytes plated on six-well tissue culture plates were infected at an MOI of 5. At 12--16 hr post-infection, cells were washed and fed with fresh growth media (Epilife media with keratinocyte supplement \[Invitrogen\] and 0.2% primocin \[Invivogen\]). At 7 days post-infection, cells were passaged onto six-well Synthemax cell culture dishes at a density of 300,000 cells/well and fed every day with pluripotency media (DMEM F-12 media \[Gibco\], 20% knockout serum replacement \[Gibco\], 0.0008% beta-mercaptoethanol \[Sigma-Aldrich, St. Louis, MO\], 1% 100 × NEAA \[Gibco\], 100 ng/ml bFGF \[human\] \[R&D\], and 0.2% primocin \[Invivogen\]. At 3 weeks post-viral transduction, iPSC colonies were picked, passaged, and clonally expanded on fresh Synthemax plates. During reprogramming and maintenance of pluripotency, cells were cultured at 5% CO~2~, 5% O~2~, and 37°C.

iPS cell differentiation {#s4-4}
------------------------

To maintain pluripotency, adult-derived iPSCs were cultured in xeno/feeder free cell culture media. To initiate differentiation, iPSCs were removed from the culture substrate via manual passage using Stem Passage manual passage rollers (Invitrogen), resuspended in embryoid body (EB) media (DMEM F-12 media \[Gibco\] containing 10% knockout serum replacement \[Gibco\], 2% B27 supplement \[Gibco\], 1% N2 supplement \[Gibco\], 1% L-glutamine \[Gibco\], 1% 100 × NEAA \[Gibco\], 0.2% primocin \[Invivogen\], 1 ng/ml noggin \[R&D Systems, Minneapolis, MN\], 1 ng/ml Dkk-1 \[R&D Systems\], 1 ng/ml IGF-1 \[R&D Systems\], and 0.5 ng/ml bFGF \[R&D Systems\]), and plated at a density of ∼50 cell clusters/cm^2^ on ultra low adhesion culture plates (Corning, Lowell, MA). Cell clusters were cultured for 5 days as indicated above, after which the EBs were removed, washed, and plated at a density of 25--30 EBs/cm^2^ in fresh differentiation media 1 (DMEM F-12 media \[Gibco\], 2% B27 supplement \[Gibco\] 1% N2 supplement \[Gibco\], 1% L-glutamine \[Gibco\], 1% 100 × NEAA \[Gibco\] 10 ng/ml noggin \[R&D Systems\], 10 ng/ml Dkk-1 \[R&D Systems\], 10 ng/ml IGF-1 \[R&D Systems\] and 1 ng/ml bFGF \[R&D Systems\]) in six-well Synthemax culture plates. Cultures were fed every other day for 10 days with differentiation media 1. For the following 6 days, cultures were fed with differentiation media 2 (differentiation media 1 + 10 μM of the Notch signaling inhibitor, DAPT \[Calbiochem, Gibbstown, NJ\]). For the following 12 days, cultures were fed with differentiation media 3 (differentiation media 2 + 2 ng/ml of aFGF \[R&D Systems\]). To enhance pigmentation and eyecup-like structure formation, cells were passaged at day 50--70 in fresh cell culture plates coated as described above and cultured for up to 150 days in differentiation media 4 (DMEM F-12 media \[Gibco\], 2% B27 supplement \[Gibco\] 1% N2 supplement \[Gibco\], 1% L-glutamine \[Gibco\], 1% 100 × NEAA \[Gibco\]).

Teratoma formation {#s4-5}
------------------

To validate that generated iPSCs were pluripotent, teratomas were generated by IM injection of 2.5 × 10^6^ undifferentiated iPSCs into immunodeficient (SCID) mice. After 90 days, tumors were excised, fixed, paraffin embedded, and sectioned.

Histology {#s4-6}
---------

Teratomas were fixed in 10% formalin for 24 hr prior to dehydration and mounting in paraffin wax (VWR). Samples were sectioned at 6 μm and H&E staining was performed using standard protocols.

Immunostaining {#s4-7}
--------------

Cells were fixed in a 4% paraformaldehyde solution and immunostained as described previously ([@bib60], [@bib59], [@bib58]). Briefly, cells/tissues were incubated overnight at 4°C with antibodies targeted against either GFAP (MAB360; Millipore, Billerica, MA) or αSMA (ab5694; Abcam, Cambridge, MA) for teratoma formation or ZO-1 (MABT11; Millipore), PAX6 (MAB5552; Millipore), bestrophin 1 (AB14929; Abcam), RPE65 (MAB5428; Millipore), acetylated tubulin (t7451; Sigma Aldrich), recoverin (AB5585; Millipore), and rhodopsin (MAB5316; Millipore) for retinal differentiation. Subsequently, Cy2- or Cy3-conjugated secondary antibodies were used (Jackson Immunochem, West Grove, PA), and the samples were analyzed using confocal microscopy. Microscopic analysis was performed such that exposure time, gain, and depth of field remained constant between experimental conditions.

Transmission electron microscopy (TEM) {#s4-8}
--------------------------------------

Eyecups at 150 days post-differentiation were fixed in one half strength Karnovsky fixative as described previously (PMID 17591911), followed by osmication, dehydration, and embedment in Epon resin. All procedures took place in the tissue culture dish. After polymerization, blocks were removed and trimmed, ultrathin sections were collected on formvar coated grids, and samples were imaged on a JEOL JEM1230 transmission electron microscope.

Immunoblotting {#s4-9}
--------------

For Western blot analysis, undifferentiated and differentiated iPSCs were homogenized in lysis buffer (50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 10 mM CaCl~2~, 1% triton X-100, 0.02% NaN~3,~ \[Sigma-Aldrich\]) and centrifuged. Supernatants were isolated and protein concentrations determined using a BCA protein assay (Pierce Chemicals, Rockford, IL). Equivalent amounts of protein (50 μg) were subjected to SDS-PAGE (8--10% acrylamide), transferred to PVDF, and probed with primary antibodies targeted against recoverin (AB 5585; EMD Millipore), rhodopsin (MAB5316; EMD Millipore), blue opsin (AB5407; EMD Millipore), red/green opsin (AB5405; EMD Millipore), GRP 78 (SC-376768; Santa Cruz), GRP 94 (SC-53929; Santa Cruz) and Actin (AB20272; Abcam; used as a loading control). Blots were visualized with ECL reagents (GE healthcare, Piscataway, NJ) and exposed to X-ray film (Fisher, Pittsburg, PA).

RNA isolation and rt-PCR {#s4-10}
------------------------

Total RNA was extracted using the RNeasy Mini-kit (Qiagen, Valencia, CA) following the provided instructions. Briefly, cells were lysed, homogenized, and ethanol was added to adjust binding conditions. Samples were spun using RNeasy spin columns, washed, and RNA was eluted using RNase-free water. 1 μg of RNA was reverse transcribed into cDNA using the random hexamer (Invitrogen, Carlsbad, CA) priming method and Omniscript reverse transcriptase (Qiagen). All PCR reactions were performed in a 40 μl reaction containing 1× PCR buffer, 1.5 mM MgCl~2~, 0.2 mM dNTPs, 100 ng of DNA, 1.0 U of AmpliTaq Gold (Applied Biosystems, Foster City, CA) and 20 pmol of each gene-specific primer. All cycling profiles incorporated an initial denaturation temperature of 94°C for 10 min followed by 35 amplification cycles with the following conditions, 30 s at 94°C, 30 s at annealing temperature of each primer, and 1 min at 72°C with a final extension at 72°C for 10 min. PCR products were separated by electrophoresis on 2% agarose gels (Invitrogen). Gene-specific primers (Invitrogen) are given in [Supplementary file 1A](#SD1-data){ref-type="supplementary-material"}.

DNA extraction {#s4-11}
--------------

Blood samples were obtained from all subjects. DNA was extracted by following the manufacturers specifications for whole blood DNA extraction using Gentra Systems' Autopure LS instrument.

Exon capture {#s4-12}
------------

Targeted enrichment of exons was performed using the Agilent SureSelect All Exon Capture platform per manufacturer's instructions. This capture platform includes 38 Mb of targeted features.

Next-generation DNA sequencing {#s4-13}
------------------------------

Sequencing of the captured genomic DNA was performed following the manufacturer's instructions on an Illumina HiSeq sequencer at the Hudson Alpha Institute in Huntsville, Alabama.

Automated DNA sequencing {#s4-14}
------------------------

Variants detected by next-generation sequencing were confirmed using automated Sanger sequencing using dye termination chemistry on an ABI 3730 sequencer. All sequencing was bi-directional.

Transplantation {#s4-15}
---------------

Newly generated 150-day photoreceptor precursor cells were transplanted into the subretinal space of P4 immune compromised *Rag1*^−/−^ x *Crb1*^−/−^ mice. 2 weeks after transplantation, mice were sacrificed and eyes were removed for histological analysis, fixed in 4% paraformaldehyde for 12 hr, embedded and sectioned on a cryostat. Sectioned mouse eyes were used for immunofluorescence analysis. Sections were blocked in 10% goat serum 3% BSA and 0.2% triton X-100 for 1 hr, and then incubated with anti-Tra-1-85 (MAB4385; Millipore), and recoverin antibodies (AB5585; Millipore) followed by visualization with Cy2- and Cy3-conjugated secondary antibodies (Jackson Immunochem, West Grove, PA). Sections were assessed by confocal microscopy.
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(**A**) Prioritization of exome variants. (**B**) Gene-specific primer sequences used for rt-PCR. F = forward primer and R= reverse primer.
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eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://elife.elifesciences.org/review-process)). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

Thank you for sending your work entitled "Patient-specific iPSC-derived photoreceptor precursor cells as a means to investigate and treat retinitis pigmentosa" for consideration at *eLife*. Your article has been favorably evaluated by a Senior editor and 3 reviewers, one of whom is a member of our Board of Reviewing Editors.

The Reviewing editor and the other reviewers discussed their comments before we reached this decision, and the Reviewing editor has assembled the following comments to help you prepare a revised submission.

Tucker et al. describe a series of experiments in which a 62-year-old patient with autosomal recessive RP had his DNA analyzed by exome sequencing. Presumptive disease-causing mutations were defined in the USH2A gene and the patient's keratinocytes were harvested and converted to iPSC cells. The iPSCs were differentiated to form retina-like eye-cup structures in culture (including highly differentiated RPE), the RNA splicing defect associated with one of the patient's disease alleles was demonstrated in iPSC-derived photoreceptor-like cells in culture, and the iPSCs were transplanted into a recipient mouse retina where they integrate into the photoreceptor layer.

The significance of this work is that it demonstrates current state-of-the-art technologies both with respect to disease mutation identification and, more importantly, with respect to the reprogramming of human keratinocytes into ocular cell types. The study is one of the first to apply iPSC technology to elucidate pathogenetic mechanisms (i.e., the RNA splicing defect). The authors' success with obtaining iPSC cells from an older human subject is especially noteworthy. This manuscript will be of broad interest to those working on iPSC-based therapies. The details of the iPSC methodology will be especially useful to the ocular therapeutics community.

The experiments purporting to show differentiation of transplanted human photoreceptors are quite modest and should be described as such. There is a large scope here for artifacts. Unambiguous markers and clear morphology are required, and transplantation into different animal models may also be required. This is a central issue because at present no one has convincingly demonstrated successful transplantation of human photoreceptors. Thus, it would be useful to see a more detailed characterization of the transplanted human photoreceptors in the *Rag* KO/*Crb1* KO mouse retina. For example, a transmission EM analysis of transplanted human photoreceptors would address, at the ultra-structural level, the extent to which the human cells have acquired the morphological hallmark photoreceptors, including outer segment production. In the best case, this would include an EM label for human vs. mouse cells -- immuno-EM, presumably. A second approach to this question would be to immunostain for Tra-1-85 together with antibodies for outer segment, connecting cilium and presynaptic nerve terminal components. In the Abstract and Discussion, the authors refer to the transplanted photoreceptors as "morphologically normal rod photoreceptors", but absent a more detailed characterization that is over-stating the data. We also note that a complete analysis would include functional assays, such as single cell recording of the light response. We appreciate that this is beyond the scope of the present study, but it would be useful to summarize in the Discussion the work that remains to be done.

What follows are a series of specific comments related to the iPSC differentiation and transplantation experiments:

1\) The rationale for transplanting the iPSC cells to determine if cell replacement therapy would be possible is not clearly described, given that the mutations are still present in the new photoreceptors and the effects this may have on cell survival and function are unknown and were not investigated.

2\) The authors show a single example of an eye cup-like structure in [Figure 2E](#fig2){ref-type="fig"}. The neural retinal region of the cell clump is made up of individual neural rosettes as opposed to the laminated 3-dimensional retinal structures described as eye cup-like by others. Can the authors elaborate on their relatively flattened arrangement? In addition, how often were cell clumps with this organization observed within the cultures? The authors state that "multiple eye-cups, each at different developmental stages, were present within the same well". Can they elaborate on the different stages of retinal development observed and explain why this may be the case given their stepwise differentiation protocol?

3\) Can the authors clarify what they mean by "presumptive outer segments"? Acetylated tubulin is a marker of microtubules such as those present in the connecting cilium but it does not label photoreceptor outer segments. Immunostaining for acetylated tubulin in the retina should result in punctuate staining at the site of the connecting cilium, but not throughout the rest of the photoreceptor.

4\) The resolution of the TEM image shown in [Figure 4B](#fig4){ref-type="fig"} (to corroborate the presence of the connecting cilia) is too poor to clearly see the presence of microtubules and there is no demonstration of the photoreceptor specific 9+0 arrangement. It is therefore unclear if this is in fact a sensory non-motile cilium. Can the authors provide further TEM images to verify the claims made regarding the presence of photoreceptor connecting cilia?

5\) Given that the authors have not demonstrated clear labeling or ultrastructural morphology for either inner or outer segments present in the cultured iPS cell-derived photoreceptors, it is difficult to conclude that the rhodopsin staining observed in [Figure 4G](#fig4){ref-type="fig"} is in the "presumptive outer segment". Can the authors provide further data to support this claim?

6\) The authors conclude "our patient's photoreceptor precursor cells integrated into the outer nuclear layer and differentiated into morphologically normal rod photoreceptors". This statement implies complete photoreceptor morphology in iPS cell-derived integrated photoreceptors, including synaptic boutons, cell processes, cell body, and outer segment formation.

7\) Is two weeks sufficient time to observe mature morphological features in integrated human iPS cell-derived photoreceptors? Can the authors comment on the time taken for the morphological maturation of human photoreceptors, especially as they state that "retinal differentiation of human cells takes significantly longer" than mouse cells?

8\) Given the non-specific secondary staining of the retinal vessels in [Figure 7C](#fig7){ref-type="fig"}, can the authors provide an image of the injection site from the primary omitted control staining, as it is difficult to determine the positive staining from the non-specific background staining when using antibodies raised in mouse on mouse tissue. Other examples of human specific markers, ideally neural or photoreceptor specific, to clearly identify the iPS cell-derived cells from the host murine photoreceptors would be useful.

9\) [Figure 6C](#fig6){ref-type="fig"}: are those individual bands from the same blots/same exposure? Are their intensities directly comparable? Running the samples side-by-side on the same gel and same blot is the cleanest way to do this.

10.7554/eLife.00824.015

Author response

*The experiments purporting to show differentiation of transplanted human photoreceptors are quite modest and should be described as such. There is a huge scope here for artifacts. Unambiguous markers and clear morphology are required, and transplantation into different animal models may also be required. This is a central issue because at present no one has convincingly demonstrated successful transplantation of human photoreceptors. Thus, it would be useful to see a more detailed characterization of the transplanted human photoreceptors in the Rag KO/Crb1 KO mouse retina. For example, a transmission EM analysis of transplanted human photoreceptors would address, at the ultra-structural level, the extent to which the human cells have acquired the morphological hallmark photoreceptors, including outer segment production. In the best case, this would include an EM label for human vs. mouse cells -- immuno-EM, presumably. A second approach to this question would be to immunostain for TRA1-85 together with antibodies for outer segment, connecting cilium, and presynaptic nerve terminal components*.

We agree that if the primary purpose of the paper were to convincingly demonstrate the feasibility of a stem-cell-based photoreceptor replacement therapy, a complete demonstration of photoreceptor cell identity, synaptic connectivity, and electrophysiologic and psychophysical function would be required. In fact, such studies are underway in our laboratories using a variety of immune deficient retinal degenerative mouse strains (Rag-Rho^-/-^, Rag-Mak^-/-^, Rag-Crb1^-/-^, Rag-Prph2^-/-^ & Rag-Cep290^-/-^) and a variety of different patient specific cell lines (from control individuals and patients affected with heritable retinal degeneration). However, the primary goal of the current study was to demonstrate that photoreceptor precursor cells could be generated from the skin of a patient in the seventh decade of life affected with a rare inherited retinal disease (retinitis pigmentosa), and that these cells could be used to demonstrate the pathogenicity of a recently described non-exomic mutation in a large retina-specific gene (*USH2A*). Given this, we have decided to remove the words "and treatment" from the title, because we now realize that these words would suggest to some readers that the types of transplantation detail asked for by the reviewers would be found in this paper.

The rationale for the transplantation portion of this paper was to show that the identified *USH2A* mutations do not result in gross developmental abnormalities of the photoreceptors; that is, it is a component of our investigation of the pathophysiology of the mutations. However, in response to the reviewers' comments we have provided further information regarding secondary control staining ([Figure 7---figure supplement 1](#fig7s3){ref-type="fig"} shows Tra-1-85 and Cy3 secondary staining of the contralateral sham injected eye).

*In the Abstract and Discussion, the authors refer to the transplanted photoreceptors as "morphologically normal rod photoreceptors", but absent a more detailed characterization that is over-stating the data*.

As noted above, our intent was to demonstrate that the patient's *USH2A* mutations did not cause gross developmental abnormalities of the photoreceptor structure. However, we agree with the reviewers that without a more complete characterization, the phrase "morphologically normal rod photoreceptors" is an overstatement. Therefore, we have altered the text to say "morphologically and immunohistochemically recognizable photoreceptors" instead of "morphologically normal rod photoreceptors".

*We also note that a complete analysis would include functional assays, such as single cell recording of the light response. We appreciate that this is beyond the scope of the present study, but it would be useful to summarize in the Discussion the work that remains to be done*.

We agree with the reviewers and we have added a paragraph to the Discussion to outline some of the work that will need to be done before asserting the feasibility of iPSC-derived retinal therapies in humans (starting "However, much work remains to be done...").

*What follows are a series of specific comments related to the iPSC differentiation and transplantation experiments*:

*1) The rationale for transplanting the iPSC cells to determine if cell replacement therapy would be possible is not clearly described, given that the mutations are still present in the new photoreceptors and the effects this may have on cell survival and function are unknown and were not investigated*.

We have added and altered the following sentences in the Results section to clarify our rationale for the transplantation portion of the paper:

"The ability to transplant such cells into animals with retinal degeneration will also be valuable as part of the vision scientist's armamentarium for exploring the pathophysiologic mechanism of specific mutations that are identified in patients. To test whether patient-specific photoreceptor precursor cells isolated from the neural retina layer of human iPSC-derived eyecups could give rise to new photoreceptor cells in animals for the latter purpose, a series of transplantation experiments were performed."

*2) The authors show a single example of an eye cup-like structure in* [*Figure 2E*](#fig2){ref-type="fig"}*. The neural retinal region of the cell clump is made up of individual neural rosettes as opposed to the laminated 3-dimensional retinal structures described as eye cup-like by others. Can the authors elaborate on their relatively flattened arrangement? In addition, how often were cell clumps with this organization observed within the cultures? The authors state that "multiple eye-cups, each at different developmental stages, were present within the same well". Can they elaborate on the different stages of retinal development observed and explain why this may be the case given their stepwise differentiation protocol*?

We use the term "eye-cup-like structures to refer to the circular and bilaminar arrangement of cells with photoreceptor precursors on the inside and RPE precursors on the outside. These eye-cup-like structures are seen routinely in our culture system, i.e., on average there are 2--3 of these structures in each well of a 6 well plate. In some cases, the structures are not as well organized as the one studied most extensively in this paper and consist of RPE precursors surrounding a confluent disk of photoreceptor rosettes. In all cases, the pigmented RPE cells appear first and the nonpigmented photoreceptor precursors appear later, suggesting that the former induce or otherwise give rise to the latter through some as yet uncharacterized mechanism.

To acknowledge and show the variability of the eyecup anatomy we observe, we now include the following sentence in the Results section and include some more images of multiple eyecup-like structures in [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}:

"In some cases these RPE/neural units extended into C-shaped eyecup-like structures ([Figure 2 D & E](#fig2){ref-type="fig"}), while in others the central cavity did not form and the structure consisted of a circular sheet of neural cells surrounded by a pigmented epithelium ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"})."

The reason that our eyecup like structures develop in a planar fashion is that we grow them in a tissue culture dish and not in suspension culture as reported by Meyer and Eiraku. We have now added the following sentences to explain this, as well as to give a couple of practical advantages of our approach:

"The reason that these eyecup-like structures develop in a planar fashion instead of the spheres reported by both Meyer et al. 2011 and Eiraku et al. 2012 is that we grow these cells under adherent conditions in tissue culture dishes coated with collagen, laminin, and fibronectin, while spheres are grown in suspension. Although there will undoubtedly be advantages of both approaches in different situations, two advantages of this planar system is that the neural cells in the center of the eyecup do not necrose for lack of oxygen and the firm attachment to the underlying substrate allows homogeneous biopsies to be taken from the eyecups for subculture and analysis."

*3) Can the authors clarify what they mean by "presumptive outer segments"? Acetylated tubulin is a marker of microtubules such as those present in the connecting cilium but it does not label photoreceptor outer segments. Immunostaining for acetylated tubulin in the retina should result in punctuate staining at the site of the connecting cilium, but not throughout the rest of the photoreceptor*.

We agree with the reviewers that antibodies to acetylated tubulin label the connecting cilia of photoreceptors and not the outer segments themselves. In the original manuscript, we used the term "presumptive outer segments" to refer to the tips of the ciliated structures that we observed to express rhodopsin. However, we agree that we need to be very careful not to equate "ciliated structures" with "outer segments". We have therefore reworded the corresponding section (starting "To determine whether cells contained within non-pigmented neural rosettes") to reflect this.

*4) The resolution of the TEM image shown in* [*Figure 4B*](#fig4){ref-type="fig"} *(to corroborate the presence of the connecting cilia) is too poor to clearly see the presence of microtubules and there is no demonstration of the photoreceptor specific 9+0 arrangement. It is therefore unclear if this is in fact a sensory non-motile cilium. Can the authors provide further TEM images to verify the claims made regarding the presence of photoreceptor connecting cilia*?

We agree with the reviewers that [Figure 4B](#fig4){ref-type="fig"} does not convincingly show an "axoneme" and we do not have any more convincing TEM images of the cilia of the photoreceptors in hand. We have therefore altered this sentence to read:

"TEM analysis further confirmed the existence of cilia with clearly identifiable basal bodies ([Figure 4B](#fig4){ref-type="fig"} arrowhead)."

*5) Given that the authors have not demonstrated clear labeling or ultrastructural morphology for either inner or outer segments present in the cultured iPS cell-derived photoreceptors, it is difficult to conclude that the rhodopsin staining observed in* [*Figure 4G*](#fig4){ref-type="fig"} *is in the "presumptive outer segment". Can the authors provide further data to support this claim*?

The term "presumptive outer segment" has been replaced by "acetylated tubulin positive structures concentrated at the luminal surface of the rosettes".

*6) The authors conclude "our patient\'s photoreceptor precursor cells integrated into the outer nuclear layer and differentiated into morphologically normal rod photoreceptors". This statement implies complete photoreceptor morphology in iPS cell-derived integrated photoreceptors, including synaptic boutons, cell processes, cell body, and outer segment formation*.

*USH2A* is known to be a large matrix molecule normally expressed at the base of the connecting cilium and our goal was to show that disease-causing mutations in *USH2A* did not result in gross developmental abnormalities in the inner and outer segments of photoreceptors derived from iPS cells. As noted above, we agree that without a more complete characterization the phrase "morphologically normal rod photoreceptors" is an overstatement. Therefore, we have altered the text in four places to say "morphologically and immunohistochemically recognizable photoreceptor cells".

*7) Is two weeks sufficient time to observe mature morphological features in integrated human iPS cell-derived photoreceptors? Can the authors comment on the time taken for the morphological maturation of human photoreceptors, especially as they state that "retinal differentiation of human cells takes significantly longer" than mouse cells*?

The reviewers have touched upon a very important point, i.e., the importance of transplanting mature photoreceptor precursor cells rather than immature retinal progenitor cells that require extensive post-transplant differentiation. Following a 2006 publication in *Nature* from Robin Ali's group describing the transplantation of mature post-mitotic photoreceptor precursor cells, it became clear that for optimal results, the majority of the transplanted cells' differentiation needs to occur *ex vivo* prior to transplantation. In the experiment reported here, the cells have been differentiated for more than 150 days before the transplantation so that the difference in differentiation time between mouse and human has already been accommodated.

The second aspect of the retinal development question that one needs to consider in a transplantation experiment is how long it takes for the cells to migrate into the proper position, develop polarity, extend axons, establish synapses, etc. The length of time required for human cells to do this in a mouse is unknown at present and was not addressed in this paper. To date, we have only looked at a single time point (2 weeks) but in this one experiment we were pleased to find the degree of integration, polarization, and process extension that we did (which is why we included it in this paper). However, many more experiments with many different time points will be needed to establish the true time course of the post transplant maturation and the physiological function of the transplanted cells.

*8) Given the non-specific secondary staining of the retinal vessels in* [*Figure 7C*](#fig7){ref-type="fig"}*, can the authors provide an image of the injection site from the primary omitted control staining, as it is difficult to determine the positive staining from the non-specific background staining when using antibodies raised in mouse on mouse tissue. Other examples of human specific markers, ideally neural or photoreceptor specific, to clearly identify the iPS cell-derived cells from the host murine photoreceptors would be useful*.

An example of a control sham injection stained with Tra-1-85 and labeled with mouse Cy3 secondary is now presented in [Figure 7---figure supplement 1](#fig7s3){ref-type="fig"}.

*9)* [*Figure 6C*](#fig6){ref-type="fig"}*: are those individual bands from the same blots/same exposure? Are their intensities directly comparable? Running the samples side-by-side on the same gel and same blot is the cleanest way to do this*.

The bands originally presented were from the same blots with the same exposure and were directly comparable. To prevent bleed through and cross contamination between lanes we routinely skip lanes between samples on western blots. Digital removal of the skipped lanes (indicated by the white lines on the originally submitted figure) allowed us to present the data in a more compact fashion. However, to make it clear that the lanes are truly comparable, we have repeated each of the blots in question without skipping lanes and now present them without separation markers.
